Dr. Thomas Nittoli, Regeneron Pharmaceuticals, Inc - Qepler Summits And Conferences

Dr. Thomas Nittoli

Director, R&D Chemistry Therapeutic Proteins
Regeneron Pharmaceuticals, Inc
New York, USA
Regeneron (NASDAQ: REGN) is a leading biotechnology company using the power of science to bring new medicines to patients in need.

Tom Nittoli has over 20 years of experience in the pharmaceutical industry and is currently Director of R&D Chemistry. Tom joined Regeneron in 2010 to advance conjugated antibodies and proteins from discovery to development. Since joining Regeneron, he has developed a variety of small molecules for protein conjugation, lead diverse teams of discovery ADC scientists, and lead cGMP synthesis and conjugation campaigns.

Prior to Regeneron, Tom held positions at Pfizer, Wyeth, and CIBA-Giegy. He holds a PhD from the department of chemistry SUNY Stony Brook and was a post-doctoral fellow at the University of Pennsylvania.

Related Sessions:

Highly Potent APIs
Summit 2019

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 20 Feb 2019
  • Berlin, DE
  • Pharma
Day 1: Wednesday, 20 February 2019
CASE STUDY: Novel Antibody Drug Conjugate Manufacturing - Synthesis, Conjugation, and Coordination.
  • Synthesis and conjugation:
    • Technology transfer
    • Scale-up
    • Qualification
    • ADC Toxicology lot
    • ADC GMP lot
View Details